AzTrials
AzTrials

Pancreatic Cancer With Liver MetastasesPOligNCT07446946

Surgical Management of Pancreatic Cancer With Liver Metastasis (Oligometastasis)

An observational study of Pancreatic Cancer With Liver Metastases, run by Richard Hunger.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Pancreatic cancer is one of the most serious forms of cancer. When it has already spread to the liver, treatment usually consists of chemotherapy rather than surgery. However, in recent years, some hospitals have begun removing both the pancreatic tumor and liver metastases during the same operation in carefully… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pancreatic Cancer With Liver Metastases
How many people
68,303 participants
Where
No sites listed yet
Study dates
1 Jan 2010to 31 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Whole German Population

Who may be able to join

  • C25 as primary diagnosis
  • pancreatic resection (OPS:5-524, 5-525)

Who cannot join

  • Missing data on age or sex
  • transplantation procedures
  • Patients with a total pancreatectomy following a partial pancreatic resection during the same hospitalization

About this study

Pancreatic cancer is one of the most serious forms of cancer. When it has already spread to the liver, treatment usually consists of chemotherapy rather than surgery. However, in recent years, some hospitals have begun removing both the pancreatic tumor and liver metastases during the same operation in carefully selected patients. This approach remains controversial, and it is unclear how often it is performed in everyday clinical practice and whether it is safe.

The aim of this study was to better understand current practice patterns in Germany and to evaluate the short-term safety of simultaneous pancreatic and liver surgery. Using nationwide hospital data, we examined all adult patients who underwent pancreatic resection for a malignant pancreatic tumor over a 14-year period.

Read more

The study was designed to test several key hypotheses. First, we hypothesized that simultaneous resection of pancreatic tumors and liver metastases is not an exceptional event but is already being performed in routine clinical care. Second, we examined whether adding liver surgery increases the risk of dying during the hospital stay compared to pancreatic surgery alone. Third, we investigated whether the extent of liver resection (minor versus major anatomical procedures) influences perioperative risk. Finally, we assessed whether hospital experience and surgical case volume affect patient safety in this complex setting.

Because the data were derived from a nationwide administrative registry, the study focuses on short-term outcomes during hospitalization. It does not address long-term survival or the overall oncologic benefit of combined surgery. Instead, the purpose of this analysis is to provide objective real-world data on how frequently this surgical strategy is used and whether it appears to be feasible from a perioperative safety perspective.

Read the detailed description

Study Design and Registry Framework This investigation represents a nationwide retrospective cohort study based on the German Diagnosis-Related Group (DRG) hospital discharge database covering the period 2010-2023. The DRG system constitutes a mandatory administrative registry capturing all inpatient hospitalizations across Germany, thereby providing full national coverage without center-level voluntary participation bias.

The registry includes patient demographics, ICD-10 diagnosis codes, OPS procedure codes, discharge status, and institutional identifiers. For this study, all adult patients (≥18 years) with a principal diagnosis coded as malignant neoplasm of the pancreas (ICD-10 C25) who underwent pancreatic resection were included.

Quality Assurance Plan The German DRG registry operates under a legally mandated standardized coding framework. Coding is performed by trained hospital coders and subject to institutional internal audits as well as external audits by health insurance funds and the Medical Service of Health Insurance (MD). Financial reimbursement is directly linked to coding accuracy, creating systematic incentives for data validity.

For this study:

Only validated national DRG datasets were used. Data were obtained from the Federal Statistical Office. All data were anonymized prior to analysis. Logical consistency checks were performed before statistical analysis. No site-level monitoring was required, as this is a population-based administrative dataset.

Data Validation and Registry Procedures

Data validation in the DRG system includes:

Automated plausibility checks at the hospital level. Cross-validation between diagnosis and procedure codes. Reimbursement-driven coding audits. Periodic national validation procedures.

Before analysis, additional study-specific validation steps were performed:

Removal of patients with missing age or sex. Hierarchical ranking of pancreatic procedures to avoid double counting. Exclusion of implausible combinations (e.g., total pancreatectomy following partial resection within same admission).

Verification of coding consistency between C78.7 (secondary liver malignancy) and liver resection codes.

Data Checks and Internal Consistency

Data were checked against predefined logical rules:

Age ≥18 years. Valid combinations of pancreatic resection types. Liver resection categorized as non-anatomic or anatomic based on OPS coding. Cross-check of metastatic liver diagnosis (C78.7) with liver resection procedures.

Range checks for continuous variables (e.g., age). Inconsistencies were excluded or corrected according to predefined rules.

Source Data Verification

As this is a nationwide administrative dataset, direct medical record review was not possible. However, source data integrity is supported by:

Mandatory hospital coding standards. Financial audit procedures. External audits by statutory health insurance authorities. National validation studies demonstrating reliability of DRG coding for major surgical procedures.

Therefore, indirect source data verification is inherent to the registry's structure, although patient-level chart verification was not performed.

Data Dictionary

Key variables included:

Demographics:

  • Age (years)
  • Sex (male/female)

Diagnoses:

  • ICD-10 C25 (malignant neoplasm of pancreas)
  • ICD-10 C78.7 (secondary malignant neoplasm of liver) Comorbidities defined via Charlson algorithm (Quan et al.)

Procedures: OPS codes for:

  • Distal pancreatectomy
  • Pancreatic head resection
  • Total pancreatectomy
  • Liver wedge resection
  • Segmentectomy
  • Hemihepatectomy
  • Thermal ablation

Outcomes:

In-hospital mortality (binary) Failure to rescue (death after major complication) Institutional Variable

Annual hospital caseload categorized as:

<10, 10-19, 20-49, ≥50 pancreatic resections/year

Coding systems used:

ICD-10-GM (German modification) OPS (German procedure coding system) Charlson Comorbidity Index (Quan adaptation)

Data Management:

  • Secure data storage.
  • Anonymized dataset.
  • Reproducible R scripts.

Analysis Workflow:

  • Descriptive statistics.
  • Group comparisons.
  • Multivariable logistic regression.
  • Volume-outcome marginal effect estimation.

Change Management Any analytic modification required documentation and version tracking in the statistical analysis script.

Sample Size Assessment

This study is based on complete nationwide capture (N = 68,303 resections). Given the large cohort size:

Statistical power was sufficient to detect small effect sizes. Mortality differences ≥1% were detectable with high precision. No formal prospective power calculation was required due to exhaustive national sampling.

The subgroup with simultaneous liver resection (n=2,447) provided adequate power for multivariable modeling.

Plan for Missing Data Administrative datasets typically have minimal missingness for key variables (age, sex, discharge status).

Approach:

Exclusion of patients with missing age or sex. No imputation performed. Comorbidity coding assumed absent if not coded. Logical inconsistencies were excluded prior to analysis. No multiple imputation was required.

Statistical Analysis Plan

Primary Objective:

Assess association between simultaneous liver resection and in-hospital mortality.

Secondary Objective:

Assess failure to rescue and volume-outcome relationships.

Analytical Principles

  • Two-sided hypothesis testing.
  • Significance threshold p < 0.05.
  • Reporting of odds ratios with 95% confidence intervals.

Methods:

Descriptive analysis (means, medians, proportions). Chi-square and Wilcoxon tests. Multivariable logistic regression using Firth's correction to reduce small-sample bias.

Adjustment variables:

  • Age group
  • Sex
  • Pancreatic procedure type
  • Individual Charlson comorbidities
  • Hospital case volume
  • Year of operation

Subgroup analyses:

  • Anatomic vs non-anatomic liver resection.
  • Volume-stratified outcome modeling.
  • Marginal standardized predicted probabilities for hospital volume categories.

All analyses were performed in R (version 4.3).

Limitations of Registry-Based Design No histopathological differentiation beyond ICD-10 C25. No systemic therapy data. No long-term survival. No 90-day mortality. No tumor burden quantification. Heterogeneous patient selection likely.

Summary This registry-based nationwide analysis applies structured validation procedures, predefined analytic rules, and standardized coding systems to evaluate the safety of simultaneous pancreatic and liver resections. While administrative data limit oncologic interpretation, the methodological framework ensures robust short-term safety assessment across a complete national cohort.

Keywords
Pancreatic cancer, liver metastases, oligometastatic disease, pancreatic resection, hepatectomy
Medical subject headings
Pancreatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07446946
Study groupRoleWhat they receive
Pancreatic cancer with liver metastasesPrimary diagnosis C25 and side diagnosis C78.7
Pancreatic cancer without liver metastasesPrimary diagnosis C25 and without side diagnosis C78.7

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 30-Day in-hospital mortality

    Postoperative death within 30 days after index surgery

    Measured: 30 days

  2. Failure-to-Rescue

    Death after the occurrence of a major complication

    Measured: Within 30 days after index surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Mar 2026
  2. Study start1 Jan 2010
  3. Primary completion31 Dec 2023
  4. Study completion31 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
68,303 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07446946
Sponsor's protocol ID
POlig
Acronym
POlig
Status last verified
Feb 2026
First submitted
26 Feb 2026
Last updated
3 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The analyzed data is held by the Federal Statistical Office of Germany and the Statistical Offices of the Federal States. The data is not publicly available.

Questions about this trial

What is this clinical trial studying?

An observational study of Pancreatic Cancer With Liver Metastases, run by Richard Hunger.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

30-Day in-hospital mortality (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in